Advertisement
Canada markets open in 5 hours 25 minutes
  • S&P/TSX

    22,375.83
    +116.63 (+0.52%)
     
  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     
  • DOW

    39,387.76
    +331.36 (+0.85%)
     
  • CAD/USD

    0.7308
    -0.0004 (-0.05%)
     
  • CRUDE OIL

    79.83
    +0.57 (+0.72%)
     
  • Bitcoin CAD

    86,344.45
    +2,457.38 (+2.93%)
     
  • CMC Crypto 200

    1,356.76
    -1.25 (-0.09%)
     
  • GOLD FUTURES

    2,373.80
    +33.50 (+1.43%)
     
  • RUSSELL 2000

    2,073.63
    +18.49 (+0.90%)
     
  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     
  • NASDAQ futures

    18,249.00
    +34.50 (+0.19%)
     
  • VOLATILITY

    12.78
    +0.09 (+0.71%)
     
  • FTSE

    8,423.77
    +42.42 (+0.51%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • CAD/EUR

    0.6777
    -0.0001 (-0.01%)
     

Celldex to Participate in Upcoming Investor Conferences

HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences in November:

  • Guggenheim 3rd Annual Healthcare Talks Neuro/Immunology Conference on Tuesday, November 16, 2021 at 10:20 a.m. ET

  • Jefferies London Healthcare Conference available on-demand beginning Thursday, November 18, 2021 at 3:00 a.m. ET / 8:00 a.m. GMT

  • Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 8:25 a.m. ET

Webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. Replays will be available for 30 days following the events.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

ADVERTISEMENT

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Senior Director, Investor Relations & Corporate Communications
(484) 788-8560
ptill@celldex.com